U.S. markets closed

Aspira Women's Health Inc. (AWH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7800-0.1700 (-3.43%)
At close: 4:00PM EDT

4.7800 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close4.9500
Bid4.2300 x 800
Ask5.0900 x 1100
Day's Range4.7300 - 5.0100
52 Week Range1.9000 - 10.5400
Avg. Volume662,977
Market Cap535.102M
Beta (5Y Monthly)3.15
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Earnings Preview: Aspira (AWH) Q1 Earnings Expected to Decline

    Earnings Preview: Aspira (AWH) Q1 Earnings Expected to Decline

    Aspira (AWH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • A Look At The Fair Value Of Aspira Women's Health Inc. (NASDAQ:AWH)
    Simply Wall St.

    A Look At The Fair Value Of Aspira Women's Health Inc. (NASDAQ:AWH)

    In this article we are going to estimate the intrinsic value of Aspira Women's Health Inc. ( NASDAQ:AWH ) by projecting...

  • Aspira Inks Agreement For Ovarian Cancer Test; Shares Rise 32% Post-Market

    Aspira Inks Agreement For Ovarian Cancer Test; Shares Rise 32% Post-Market

    Bioanalytical company Aspira Women’s Health has entered into an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Medical University Lodz to study their microRNA technology with Aspira’s solutions. Aspira Women’s Health (AWH) will evaluate the combination of these two technologies to develop ovarian cancer detection tests. Shares of the company jumped about 32% in Thursday’s extended trading session. Aspira’s Chief Scientific Officer, Lesley Northrop, Ph.D., FACMG, said, “Over the past 10 years, Aspira has been actively developing and evaluating numerous technologies that will advance early detection of ovarian cancer.” Northrop further added, “With our focused expertise and experience in multi-modality detection of ovarian cancer risk, we have the foundation to implement a liquid biopsy test specific to early stage disease detection.” Additionally, the company came out with its 4Q results. It posted a net loss of $0.58 per share, which was wider than analysts’ expectations of a net loss of $0.04 per share. Revenues, driven by higher test volumes, increased 10.7% year-over-year to $1.45 million, topping analysts’ estimates by $0.15 million. (See Aspira Women’s Health stock analysis on TipRanks) Recently, Cantor Fitzgerald analyst Kyle Mikson gave the stock a Buy rating with a price target of $10 (49% upside potential). Mikson thinks Aspira’s OVA1plus test “could become the standard of care” and the company’s product pipeline has “significant potential revenue opportunity.” Aspira scores a 6 out of 10 from TipRanks’ Smart Score rating system, indicating that the stock may perform in line with the broader market. Shares have rallied about 852.3% over the past year. Related News: ViacomCBS Drops 23% After Pricing New $3B Stock Sale Evolus Slips 10% On Wider-Than-Expected 4Q Loss Winnebago Crushes 2Q Estimates On Strong Consumer Demand More recent articles from Smarter Analyst: NextDecade Shares Jump 23% After Hours On Carbon Storage Agreement Lamb Weston To Expand French Fry Capacity in China Annaly Capital To Sell Commercial Real Estate Unit For $2.33 Billion BWX Tech Clinches $28 Million Defense Contract